News

Almirall: COPD drug approved
Enlarge image

BusinessSpain

Almirall: COPD drug approved

27.07.2012 - Spanish drugmaker Almirall S.A.'s inhaled treatment for lung disease COPD has been approved in all EU member states, plus Iceland and Norway.

The approval by the European Commission was expected after the CHMP gave the twice-daily drug a positive opinion in May covering use as a maintenance bronchodilator treatment to relieve symptoms in patients with chronic obstructive pulmonary disease (COPD). US approval is expected in July.

Florence-based Menarini Group will have joint commercialisation rights across the majority of EU member states (excluding the UK, the Netherlands and the Nordic countries, where Almirall retains sole marketing rights for the product) as well as Russia, Turkey and other CIS countries under the brand name Bretaris Genuair, while Almirall will market the product in Europe as Eklira Genuair.

Almirall's treatment loosens the muscles around the lungs to improve airflow. COPD makes breathing difficult and is often caused by cigarette smoking, which kills between 200,000 and 300,000 people in Europe a year, Almirall said.

M&AUKIreland

08.07.2014 Abbvie is determined to bring home British rare disease specialist Shire in a merger worth £30.1bn (€37.9bn).

M&ASwitzerland

04.07.2014 Genentech, a member of Swiss Roche Group, is set to acquire US-biotech Seragon Pharmaceuticals Inc. With the move, Genentech will obtain the rights to investigational breast cancer treatments.

M&AFranceGermany

03.07.2014 Nicox S.A. is stretching beyond the European market: The French eye health specialist is set to acquire Aciex Therapeutics Inc., a US-based pharma company with several ophthalmic therapeutics nearing market maturity.

FinanceBelgium

01.07.2014 Belgian antibody specialist Ablynx has raised €41.7m through a private placement of new shares and plans on boosting their range of nanobodies in development.

BioeconomyBelgiumUK

30.06.2014 Building on a £1.2m financing round, Celtic Renewables partners with a Belgian pilot plant to bring its bio-fuel made from whisky production residue to an industrial scale.

ConventionEUUK

25.06.2014 Sun, celebrities and a scandal - the world’s largest biotech convention is getting off to an explosive start in San Diego, California.

InvestmentGermanyNetherlands

24.06.2014 Bayer Healthcare is getting back into gene therapy with a US$252m deal aimed at the development of a haemophilia A treatment.

InvestmentNetherlands

20.06.2014 Tomtom founder Pieter Geelen invests in Dutch biotech Ocello, the company behind a 3D mapping technology used for predicting drug behaviour in patients.

RegulatoryEU

17.06.2014 The member states of the European Union have agreed on a EU-wide directive for the authorisation process of genetically modified crops – with an opt-out for individual countries.

Events

All Events

Partner-Events

Vilnius (LT)

Life Sciences Baltics

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • NOVACYT (F)4.99 EUR9.67%
  • CELLECTIS (F)14.00 EUR4.56%
  • PHARMING (NL)0.53 EUR3.92%

FLOP

  • PROSENSA (NL)10.48 USD-16.29%
  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%

TOP

  • SANTHERA (CH)72.55 CHF136.7%
  • CELLECTIS (F)14.00 EUR109.0%
  • ADDEX (CH)3.62 CHF62.3%

FLOP

  • THROMBOGENICS (B)8.78 EUR-51.2%
  • MERCK KGAA (D)64.18 EUR-50.1%
  • VERONA PHARMA (UK)1.20 GBP-43.4%

TOP

  • SANTHERA (CH)72.55 CHF3564.1%
  • GW PHARMACEUTICALS (UK)432.00 GBP802.3%
  • PAION (D)2.92 EUR323.2%

FLOP

  • EVOCUTIS (UK)0.21 GBP-93.3%
  • CYTOS (CH)0.25 CHF-92.8%
  • THROMBOGENICS (B)8.78 EUR-72.8%

No liability assumed, Date: 09.07.2014